SecBot SecBot
PRESS-RELEASE ·Filed Jun 14, 2026

ZYME

Zymeworks Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong response rates in both FRα-positive and FRα-negative PROC patients position ZW191 as a potential best-in-class FRα-targeting ADC. Traders should watch for Part 2a data at a future medical meeting, which will inform dose selection and potential pivotal trial design. Given historical volatility on ZYME pipeline news, consider taking partial profits on strength.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.26
T+0 close · Jun 14, 2026 · via day close
Latest settled
+16.72%
T+60 · $27.15
Vs SPY
+15.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $23.26entry
  2. T+1 · 5mo ago −3.31%α −2.71% · $22.49
  3. T+5 · 5mo ago 0.00%α +1.38% · $23.26
  4. T+20 · 4mo ago +7.22%α +7.97% · $24.94
  5. T+60 · 2mo ago +16.72%α +15.72% · $27.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congress 2026. The drug showed a confirmed objective response rate (cORR) of 78.6% in FRα-positive platinum-resistant ovarian cancer (PROC) patients and 47.4% in FRα-negative patients, with median progression-free survival of 7.6 months. While early-stage, the data suggests ZW191 could address limitations of current FRα-targeted therapies and broaden the treatable population, representing a positive clinical catalyst for the stock.

Key Facts

  • ZW191 demonstrated a cORR of 78.6% in FRα-positive (≥75% at PS2+) PROC patients across all dose levels.
  • ZW191 demonstrated a cORR of 47.4% in FRα-negative (<75% at PS2+) PROC patients across all dose levels.
  • Overall cORR in PROC was 58.8% across all dose levels and 65.2% in the 6.4-9.6 mg/kg dose range.
  • Median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts; median duration of response was not reached.
  • Part 2a dose optimization (randomized 6.4 vs 9.6 mg/kg Q3W) has completed enrollment in ~60 PROC patients.
  • Safety profile manageable: grade ≥3 TEAEs in 55% of patients, most common neutropenia (24%), anemia (20%), thrombocytopenia (12%); 20% discontinued due to AEs.

Financial Impact

Positive catalyst for ZYME stock, but magnitude uncertain given early Phase 1 data and small sample sizes. No financial figures disclosed.

stock pricepipeline value

Risk Factors

  • Phase 1 data is early; sample sizes for subgroups not disclosed, limiting statistical reliability.
  • Safety profile includes 20% discontinuation rate due to AEs; grade ≥3 neutropenia (24%) and anemia (20%) are notable.
  • Competition from approved Elahere (mirvetuximab soravtansine) and other FRα-targeting ADCs in development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311472

Track record

25 reports on ZYME

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +14.38% at T+60 after the Jun 29, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 14, 2026